<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-OIN-16007780</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2016-01-17</date_registration>
      <primary_sponsor>The First Affilited Hospital of Guangxi Medical University </primary_sponsor>
      <public_title>Efficacy and safety of conditioning including idarubicin and antithymocyte globulin in sibling donor allogeneic hematopoietic stem cell transplantation for standard-risk acute leukemia</public_title>
      <acronym />
      <scientific_title>Efficacy and safety of conditioning including idarubicin and antithymocyte globulin in sibling donor allogeneic hematopoietic stem cell transplantation for standard-risk acute leukemia</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2016-01-01</date_enrolment>
      <type_enrolment />
      <target_size>one:30;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=13013</url>
      <study_type>Observational study</study_type>
      <study_design>Non randomized control</study_design>
      <phase>IV (Phase IV study)</phase>
      <hc_freetext>Acute leukemia</hc_freetext>
      <i_freetext>one:conditioning including idarubicin and antithymocyte globulin ;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Zhongming Zhang</firstname>
        <middlename />
        <lastname />
        <address>6 Shuangyong road, Qingxiu district, Nanning, Guangxi Zhuang Autonomous Region</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 15807801369</telephone>
        <email>15807801369@126.com</email>
        <affiliation>The First Affilited Hospital of Guangxi Medical University </affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Yongrong Lai</firstname>
        <middlename />
        <lastname />
        <address>6 Shuangyong road, Qingxiu district, Nanning, Guangxi Zhuang Autonomous Region</address>
        <city />
        <country1 />
        <zip />
        <telephone>13517711828</telephone>
        <email>laiyongrong@263.net</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Standard-risk acute leukemia;
2. Age: 18 to 40 years old; Gender: Male or female; 
3. Patients in the first complete remission(CR1);
4. HLA-matched or one allele mismatched sibling donor allogeneic hematopoietic stem cell transplantation;
5. In good general condition, ECOG score less than 1;
6. Enrolled patients signed informed consent. </inclusion_criteria>
      <agemin>18</agemin>
      <agemax>40</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. Cardiac dysfunction (ejection fraction less than 60%); Lung function insufficiency(obstruction and/or restrictive ventilatory disorders); Hepatic dysfunction (total bilirubin more than 34umol/L, ALTAST more than 2 times the upper limit of normal); Renal insufficiency (serum creatinine more than 130umol/L); 
2. Severe invasive fungal infections uncontrolled before transplantation; 
3. Contraindicated in using IDA, IDA total cumulative dose up to 300 mg/m2; 
4. Severe allergic on Antithymocyte globulin (anaphylactic shock or laryngeal edema); 
5. Unrelated donor or autologous allogeneic hematopoietic stem cell transplantation; reduced-intensity conditioning transplantation;
6. Other circumstances which do not meet the inclusion criteria.  </exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>the relapse of leukemia post-transplantation;graft-versus-host disease post-transplantation;2-years OS post-transplantation;2-years DFS post-tansplantation;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome />
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>self-financing</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>1990-01-01</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>